Role of exosomes in the pathogenesis of fibrotic disease
How do you propose identifying the role of exosomes in the pathogenesis of IBD, SSc and ILD and their possible detection as liquid biopsies for diagnosis and monitoring of disease progression?
Elliott Klein
Sr Principal Scientist
Boehringer Ingelheim
No further applications can be accepted at this point in time.
More information
Exosomes are extracellular particles released by the majority of cells in the human body. Their composition and function can change rapidly in response to various physiological stimuli. Due to their relatively high stability, exosomes can be detected in blood and other body fluids at a distance from their tissue of origin and their characterization can provide important information about the nature and progression of pathological processes in the body. Inflammatory bowel disease (IBD), Systemic sclerosis (Ssc) and Interstitial lung disease (ILD) share similar phenotypes of aberrant tissue remodeling (ie. fibrosis). Although substantial progress has been made in the treatment of these diseases, many patients remain without effective medications that target disease progression and tissue damage. Exosomes derived from different cell types may exert a variety of effects due to the functional presence of nucleic acids, proteins and other macromolecules. In addition to their potential use as biomarkers for disease diagnosis and progression, in depth characterization of exosomes in the context of the disease setting offers an exciting promise for the identification of contents with both pro- and anti-fibrotic properties.
The following potential approaches to answer our question include, but are not limited to the following:
- Identification and description of cellular sources of exosomes and their effect on disease-relevant pathological pathways
- Molecular analysis of the macromolecules and other active agents present in exosomes that may display protective or pathological functions relevant to the pathogenesis of IBD, Ssc or ILD
- Analysis of exosomes in biofluids such as blood, urine or saliva from patients suffering from IBD, Ssc, ILD or related diseases and identification of qualitative and/or quantitative changes of their contents due to the ongoing pathogenic processes
- Analysis of exosomes in biofluids such as blood, urine, saliva or alveolar fluid and identification of qualitative and/or quantitative changes of their contents in animal models of IBD, Ssc and ILD
- Characterization of exosome crosstalk within fibrotic tissues similar to that previously described in tumor settings (e.g. between tumor cells and cancer associated fibroblasts)
- Proposals focused on exosome functions that are unique or specific to non-human species
- Proposals lacking applications to the disease setting.
- Proposals that are focused solely on exosome biogenesis and uptake independent of the disease setting
We are open to all proposals that can fully or partially meet its requirements.
If your project is selected, you will have the opportunity to directly collaborate with the Immunology and Respiratory Disease Research team of Boehringer Ingelheim. You can expect appropriate funding for the prospective collaboration period. Your exact funding request should be outlined in your proposal. As a framework, we suggest that your initial funding request is structured in milestone and does not exceed 200,000 euros per submitted project in total.
The opportunity for a funded stay at Boehringer Ingelheim for technology exchange / training is potentially available, as is the availability of custom biological tools and reagents.
Our collaboration agreement will provide full transparency about each partner’s rights & obligations (including intellectual property rights). As part of the agreement you will be encouraged to publish following the collaboration agreement (to be negotiated in good faith).
To maintain the highest degree possible in an open innovation environment, we plan to announce the winner(s) publically and feature them on opnMe.com and our social media channels. We would guide you through this process and as part of it we would kindly ask for your upfront consent, in case our scientific jury had selected your answer.
We are seeking research collaboration proposals that contain:
- A well-structured proposal outlining a new and compelling scientific idea,
- A novel, testable working hypothesis distinct from those previously published,
- Framing the questions and the innovation aspects which includes a well thought-through project plan with key decision points and budget requirements,
- Proven track record in the required field of expertise,
- Outlining the technical feasibility of the innovative proposed approach,
- A well-structured experimental plan that will be used to test the hypothesis, and potentially existing data,
- Ability to implement the outlined solution as part of a scientific collaboration project including access to a laboratory.
Please use our answer submission template to provide a 2-3 page non-confidential proposal (available for download here).
If confidential data exists that would strengthen the proposal, please indicate that confidential information is available to share under a Confidential Disclosure Agreement (CDA). If we find the non-confidential concept proposal sufficiently interesting, we will execute a CDA for confidential discussions.
We have been looking for answers for the following scientific challenge: How do you propose identifying the role (protective or pathological) of exosomes in the pathogenesis of IBD, SSc and ILD and their possible detection as liquid biopsies for diagnosis and monitoring of disease progression?
All incoming answers accompanied by a collaboration proposal will be evaluated by a scientific jury, and, upon selection, chosen proposals are pursued through a joint collaboration with the successful applicants. Initial funding of up to 200,000 euros will be available for each selected proposal.
You are invited to submit collaboration proposals also for “expired” questions including this one.
